Abstract:

Purpose: The purpose of this study is to share our experience of long-term results by studying the epidemiological, histomorphological characteristics of the lymphoma patients who apply to our center, the treatment response rates and survival data. Tools and Methods: 228 patients who were applied to our center and diagnosed with lymphoma between 2009 and 2017 were examined retrospectively on the basis of the diagnosis groups specified in the 2016 review of the World Health Organization (WHO) ranking. Studying demographic data and disease data calculated response rates, general and non-sick survival rates. Results: 190 of the patients diagnosed with 228 lymphomas over the course of 8 years of study were Non-Hodgkin Lymphoma (NHL), 38 were Hodgkin Lymphoma (HL). 135 patients were grouped as aggressive NHL, 55 patients indolent NHL and 38 patients HL. 178 of the total 190 NHL incidents (93.7%) were B cell-based, 12 (6.3%) T cell-based. DBBHL (49.5%) was a common subtype. The media tracking time was 22.23±20.74 months. In aggressive NHL patients, overall survival (OS) was 49.94 months and non-sick survival (PFS) 49.54 months. In the indolen NHL patients, OS was 63.78 months, and PFS was 64.31 months. In HL patients, OS was 62.92 months and PFS 62.92 months.  Patients' full blood count parameters at the time of diagnosis have not been shown to affect the survival periods of ferritin and vitamin B12 levels (p>0.05). Results: Our center's lymphoma epidemicology, histopathological subtype distribution, response rates and survival data have been found to be partially similar to the data of Turkey and developing countries. It has been shown that the full blood count parameters have no effect on the survival. More work is needed, especially in aggressive NHL patients, to find new developments and different prognostic indicators that can have a positive impact on their survival periods.

Keywords: